Accelerate your RSV Programme with our RSV Human Challenge Model

On-Demand
RSV Clinical Trial

About RSV & why developing RSV antivirals and vaccines are critical Respiratory Syncytial Virus (RSV) is a common, highly contagious respiratory virus that infects the lungs and airways. While ...

About RSV & why developing RSV antivirals and vaccines are critical

Respiratory Syncytial Virus (RSV) is a common, highly contagious respiratory virus that infects the lungs and airways. While RSV often causes mild, cold-like symptoms in healthy adults, it can lead to severe lower respiratory tract disease in vulnerable populations—particularly infants, young children, older adults, and immunocompromised individuals.

 

  • High unmet medical need: Until recently, treatment options were limited and largely supportive (e.g. oxygen and fluids), with few targeted therapies available.

     

  • Protection of vulnerable populations: Effective vaccines and antivirals can prevent severe disease in infants, reduce hospitalisations in older adults, and protect those at high risk of complications.

     

  • Rapid disease progression: RSV can progress quickly to bronchiolitis or pneumonia, making early intervention with antivirals especially valuable.

     

  • Global health impact: RSV causes millions of lower respiratory infections annually worldwide, contributing significantly to infant mortality in low- and middle-income countries.

     

  • Preparedness and innovation: Advancing RSV vaccines and antivirals strengthens pandemic preparedness and accelerates innovation across respiratory virus research.

     

Together, preventive vaccines and therapeutic antivirals offer the most effective strategy to reduce RSV transmission, severity, and healthcare burden—making continued investment in RSV research and development essential.

 

Webinar Overview & Key Focus Areas

 

Join our Chief Scientific Officer, Dr Andrew Catchpole, as he takes you behind the science, sharing expert insight into RSV virus isolation, GMP manufacturing, and the robust clinical data underpinning vaccine and antiviral development.

In this exclusive webinar, you’ll learn about:

  • Proven patient recruitment strategies at hVIVO

  • End-to-end human challenge trial services, from design to delivery

  • Advanced specialist laboratory capabilities

  • RSV-hMPV-PIV trivalent vaccine challenge platform readiness

  • Strategic clinical isolate selection

  • Key insights into infection dynamics, virology, and participant symptoms

  • Comparative data on RSV-B vs RSV-A infection and incidence rates